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ABSTRACT
In randomized active-comparator controlled studies, DTaP5-HB-IPV-Hib showed comparable immunogeni-
city and safety to other licensed vaccines. This study assessed persistence of anti-hepatitis B surface antigen
(HBs) and anti-pertussis antibodies, when children were 4 to 5 years of age, 3 to 4 years after initial infant/
toddler hexavalent vaccination. This was an extension of 2 European studies in which infants/toddlers
received either DTaP5-HB-IPV-Hib or DTaP3-HB-IPV/Hib on a 2 + 1 or 3 + 1 schedule. Primary endpoints
included percentages with anti-HBs ≥10 mIU/mL, and anti-pertussis toxin (PT), anti-filamentous hemagglu-
tinin (FHA), anti-pertactin (PRN), and anti-fimbriae types 2 & 3 (FIM) greater than or equal to the lower limit of
quantitation (LLOQ). Onemonth after 2 + 1 or 3 + 1 dosing, nearly all toddlers had anti-HBs ≥10mIU/mL, and
responded to the received pertussis antigens. Approximately 3 to 4 years later, 65.8%-70.2% in the DTaP5-HB
-IPV-Hib and 82.0%-83.7% in the DTaP3-HB-IPV/Hib groups, respectively, had anti-HBs ≥10 mIU/mL.
Percentages of childrenwith pertussis antibodies above LLOQ after 2 + 1 dosingwere 58.4% and 41.5% (anti-
PT), 80.9% and 88.3% (anti-FHA), 66.1% and 72.6% (anti-PRN), and 94.4% and 3.3% (anti-FIM), in the DTaP5-
HB-IPV-Hib and DTaP3-HB-IPV/Hib groups, respectively. This study demonstrated, as expected, waning of
hepatitis B and pertussis antibodies during the 3 to 4 years after completion of a 3 + 1 or 2 + 1 hexavalent
vaccination schedule. Nonetheless, anti-HBs levels ≥10 IU/mL and detectable antibodies against acellular
pertussis antigens persisted in most study participants. The implications of these findings for the long-term
prevention of hepatitis B and pertussis are further discussed.
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Introduction
The complex recommended vaccination schedule for children
younger than 2 years of age can be cumbersome for both health-
care professionals and parents, and may lead to missed opportu-
nities for vaccination that increases the risk of epidemic outbreaks
of otherwise preventable diseases.1–3 Tohelp reduce the number of
injections at office visits, 5- and 6-valent childhood vaccines have
been long introduced in Europe, andmore recently, in the United
States. Numerous studies have shown that the use of combination
vaccines increases coverage and on-time vaccination rates.4–7
Currently, 3 hexavalent vaccines are licensed in the European
Union: Infanrix® hexa (combined diphtheria, tetanus toxoids,
acellular pertussis, hepatitis B, inactivated poliomyelitis, adsorbed
conjugated Haemophilus influenzae [DTaP3-HB-IPV/Hib];
950 μg aluminum salts per 0.5-mL dose; GlaxoSmithKline
Biologicals, Rixensart, Belgium), approved in 2000; Hexyon®
(fully liquid diphtheria, tetanus, pertussis [acellular, component],
hepatitis B [rDNA], poliomyelitis [inactivated] and Haemophilus
influenzae type b [Hib] conjugate vaccine adsorbed, [DTaP2-HB-
IPV-Hib]; 600 μg aluminum salts per 0.5-mL dose; Sanofi Pasteur
Europe, Lyon, France), approved in 2013; andVaxelis® (fully liquid
diphtheria, tetanus, pertussis [acellular component], hepatitis
B [rDNA], poliomyelitis [inactivated] andHaemophilus influenzae
type b conjugate vaccine adsorbed DTaP5-HB-IPV-Hib]; 314 μg
aluminum salts per 0.5-mLdose;MCMVaccine B. V., Leiden, The
Netherlands), approved in 2016. These vaccines are indicated for
the vaccination of infants and toddlers against the diseases caused
by these pathogens.8–10 DTaP5-HB-IPV-Hib differs fromDTaP3-
HB-IPV/Hib and DTaP2-HB-IPV-Hib, as it contains 5 acellular
pertussis antigens and utilizes a meningococcal outer membrane
protein as the conjugate for the Hib antigen. DTaP5-HB-IPV-Hib
was approved in Europe in February 2016 and in theUnited States
in December 2018 based on its similar immunogenicity and safety
compared with the other licensed comparator vaccines. To meet
a request from the EuropeanMedicines Agency (EMA), this study
was conducted to assess the long-term persistence of anti-hepatitis
B surface antigen (HBs) and anti-pertussis antibodies 3 to 4 years
after initial vaccination with the DTaP5-HB-IPV-Hib. The EMA
had previously requested persistence studies for the other hexava-
lent vaccines, DTaP3-HB-IPV/Hib and DTaP2-HB-IPV-Hib.11,12
Methods
Study design
The clinical portion of this study was conducted in Finland
from late April to early August 2016, as an extension of 2
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European pivotal studies: a study evaluating a 3 + 1 schedule
conducted in Belgium, Finland, and Germany from late
May 2011 to mid-March 2013 (NCT01341639)13 and a study
evaluating a 2 + 1 schedule conducted in Finland, Italy, and
Sweden from late November 2011 to early October 2013
(NCT01480258).14 In these randomized, double-blind trials,
infants received either a 3-dose primary series of DTaP5-HB-
IPV-Hib or DTaP3-HB-IPV/Hib at 2, 3, and 4 months of age
and a toddler dose at 12 months of age or a 2 dose primary
series of DTaP5-HB-IPV-Hib or DTaP3-HB-IPV/Hib at 2 and
4 months of age and a toddler dose at 11 to 12 months of age.
Four groups were defined according to previous vaccina-
tion schedule (3 + 1 or 2 + 1) and type of vaccine (DTaP5-HB
-IPV-Hib or DTaP3-HB-IPV/Hib) received during each study
● Group 1: DTaP5-HB-IPV-Hib (3 + 1), those previously
vaccinated with a 3-dose primary series and a toddler
dose of DTaP5-HB-IPV-Hib
● Group 2: DTaP3-HB-IPV/Hib (3 + 1), those previously
vaccinated with a 3-dose primary series and a toddler
dose of DTaP3-HB-IPV/Hib
● Group 3: DTaP5-HB-IPV-Hib (2 + 1), those previously
vaccinated with a 2-dose primary series and a toddler
dose of DTaP5-HB-IPV-Hib
● Group 4: DTaP3-HB-IPV/Hib (2 + 1), those previously
vaccinated with a 2-dose primary series and a toddler
dose of DTaP3-HB-IPV/Hib
All participants in the 3 + 1 and 2 + 1 studies received
concomitant conjugate pneumococcal vaccine (PCV13) and
rotavirus vaccine. Participants in the 3 + 1 study also received
concomitant measles-mumps-rubella-varicella vaccine.
No vaccine (eg, booster or challenge dose) was administered
as part of this extension study. The long-term persistence of
antibody to hepatitis B surface antigen (anti-HBs) was assessed
approximately 3 to 4 years after completion of a 3 + 1 or 2 + 1
schedule when children were 4 to 5 years of age. The long-term
persistence of pertussis antibodies was assessed in the 2 + 1 study
only and not the 3 + 1 study. The 3 + 1 study started and finished
earlier than the 2 + 1 study. Because the school-entry pertussis-
containing booster vaccine is given at approximately 4 years of
age in Finland, many of the children in the 3 + 1 study had
already received their pertussis school-entry booster. They were
therefore not eligible to undergo the anti-pertussis antibody
measurments in this study.
Study population
This study enrolled boys and girls who had received a complete
3-dose primary series or a complete 2-dose primary series, fol-
lowed by a toddler dose with DTaP5-HB-IPV-Hib or DTaP3-HB-
IPV/Hib as part of the pivotal 3 + 1 or the 2 + 1 studies. Exclusion
criteria included receipt of any dose of a hepatitis B- or pertussis-
containing vaccine other than the vaccines of the initial studies, or
a diagnosis of hepatitis B infection or pertussis after the initial
studies. Children were also excluded if they received immunoglo-
bulins, blood, or blood-derived products within 3months of study
initiation or any immunosuppressive therapy or immune-
modifying drugs at any time.
A child could withdraw at any time or be withdrawn at the
request of parent(s) or legal representative(s), or if the investigator
thought that continuation in the study was not in the interest of
the child. Informed consent was signed by each child’s parent(s)
or legal representative(s). The study was conducted in accordance
with the International Conference on Harmonization Good
Clinical Practices standards, the Declaration of Helsinki, and all
applicable regulatory requirements, as well as any European and/
or local applicable laws and regulations relating to the conduct of
clinical trials. It is registered in ClinicalTrials.gov with an identifier
of NCT02759354.
Immunogenicity measurements
The primary endpoints were the percentage of children with
anti-HBs concentrations ≥10 mIU/mL, and anti-pertussis toxin
(PT), anti-filamentous hemagglutinin (FHA), anti-pertactin
(PRN), and anti-fimbriae types 2&3 (FIM) concentrations
greather than or equal to the lower limit of quantitation
(LLOQ), ≥2× LLOQ, and ≥4× LLOQ, with a LLOQ of 4
enzyme-linked immunosorbent assay (ELISA) units (EU)/mL
for PT, PRN, FIM, and of 3 EU/mL for FHA. Secondary end-
points included anti-HBs, anti-PT, anti-FHA, anti-PRN and
anti-FIM geometric mean concentrations (GMCs). Endpoint
analysis was performed on the persistence analysis set approxi-
mately 4 years after the initial vaccination schedule. The per-
sistence analysis set was defined as all children previously
vaccinated with a complete 3 + 1 or 2 + 1 schedule who were
not excluded per the previously noted criteria, and for whom
immunogenicity results were available in the persistence study.
Anti-HBs was assessed using a hepatitis B-enhanced che-
miluminescence (HepB ECiQ) assay at Focus Diagnostics
Clinical Trials, San Juan Capistrano, California, USA. Anti-
PT, FHA, PRN, and FIM antibodies were assessed using an
ELISA at the Sanofi Pasteur Global Clinical Immunology
platform, Swiftwater, Pennsylvania, USA.
Safety assessments
No safety analyses were performed in this study, as no addi-
tional vaccinations were administered. Only serious adverse
events (SAEs) related to study procedures (blood sampling)
were collected.
Statistics
It was estimated that with a sample size of approximately 180
evaluable children, the half width of the 2-sided 95% confi-
dence interval (CI) was not to exceed 8% if the observed
percentages of persistence were ≥60%. This was deemed
acceptable to provide an appropriate estimate for the primary
endpoints. The statistical analyses were performed using SAS®
software version 9.2 (SAS Institute Inc., Cary, North
Carolina, USA).
For categorical variables (except antibody concentrations),
descriptive statistics of sample size, count by category, and
proportion by category are presented. For continuous vari-
ables (except antibody concentrations), descriptive statistics of
sample size, mean and standard deviation are presented. For
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antibody concentrations, descriptive statistics of sample size,
count greater than or equal to the threshold, proportion
greater than or equal to the threshold, geometric mean, and
2-sided 95% CIs are presented.
Pertussis antibody concentrations reported by the laboratory
as below the LLOQ were replaced by half of the LLOQ; those
above the upper limit of quantitation were replaced by this limit.
The 2-sided 95% CIs were provided for proportions and GMCs
were calculated for immunogenicity endpoints. CIs for propor-
tions were based on the exact method for binary variables.15 CIs
for GMCs were calculated using the t distribution and sample
variance of logarithms of individual concentrations.
Results
Study population
In the original 3 + 1 study, 1217 children were randomized, and
in the original 2 + 1 study, 1315 children were randomized. Of
these children (n = 2532), 760 were screened for possible inclu-
sion into this study, with 754 children enrolled and 752 included
in the persistence analysis set. No child screened was found to
have had either hepatitis B or pertussis infection. All 752 chil-
dren were evaluable for anti-HBs analysis; however, only those
who had participated in the 2 + 1 study (n = 371) were included
in pertussis follow-up (see Methods). Demographic data are
presented in Table 1. The 3 + 1 and 2 + 1 persistence study
cohorts were very similar to the original study cohorts in terms
of female:male ratio and mean age at toddler dose.
Hepatitis B immunogenicity
All of the children (100%) in the persistence study cohort had
seroconverted (ie, achieved anti-HBs ≥10 mIU/mL) 1 month
after the 3 + 1 vaccination and 2 + 1 schedules with DTaP5-
HB-IPV-Hib or DTaP3-HB-IPV/Hib, reflecting robust hepatitis
B responses for both vaccine groups. These high seroconversion
rates in the persistence study cohort were consistent with the
anti-HBs seroconversion rates (>99% in both vaccine groups
following the 3 + 1 schedule and >98% in in both vaccine groups
following the 2 + 1 schedule) in the overall study populations
(Supplemental Tables 1 and 2). The percentages of toddlers with
anti-HBs ≥100 mIU/mL were also similar between DTaP5-HB-
IPV-Hib and DTaP3-HB-IPV/Hib in the 3 + 1 schedule (96.8%
and 98.4%, respectively, Table 2) and in the 2 + 1 schedule (97.6%
and 97.7%, respectively, Table 2), with overlapping 95% CIs. The
anti-HBsGMCs after the toddler dose were lower for DTaP5-HB
-IPV-Hib compared with DTaP3-HB-IPV/Hib, with overlap-
ping 95% CIs for the 3 + 1 schedule, but non-overlapping 95%
CIs for the 2 + 1 schedule (Table 2).
The persistence of anti-HBs was lower after DTaP5-HB-
IPV-Hib than DTaP3-HB-IPV/Hib. Approximately 4 years
after completion of a 3 + 1 schedule, the percentage of
children with anti-HBs ≥10 mIU/mL was 70.2% (95% CI,
63.1%–76.5%) in Group 1 and 82.0% (95% CI, 75.8%–
87.2%) in Group 2. Of those who received the 2 + 1 schedule,
the percentage of children with anti-HBs ≥10 mIU/mL was
65.7% (95% CI, 58.3%–72.6%) in Group 3 and 83.7% (95% CI,
77.6%–88.6%) in Group 4. The persistence of anti-HBs GMCs
across study groups were consistent with the initial GMC
results, with lower levels at 4 years after completion of the
original schedules of DTaP5-HB-IPV-Hib (Table 2).
Pertussis immunogenicity
Approximately 4 years after completion of the 2 + 1 schedule, the
proportions of children with antibodies above LLOQwere 58.4%
and 41.5% for anti-PT, 80.9% and 88.3% for anti-FHA, 66.1%
and 72.6% for anti-PRN, and 94.4% and 3.3% for anti-FIM in the
DTaP5-HB-IPV-Hib and the DTaP3-HB-IPV/Hib groups,
respectively (Table 3). The 95% CIs overlapped for DTaP5-HB-
IPV-Hib and DTaP3-HB-IPV/Hib for FHA and PRN but were
non-overlapping for PT and FIM. In the original 2 + 1 study, all
of these percentages were 100% 1 month after the 2 + 1 vaccina-
tion schedule with DTaP5-HB-IPV-Hib or DTaP3-HB-IPV
/Hib, except for FIM, of which 100% of children in the DTaP5-
HB-IPV-Hib group had anti-FIM antibodies above LLOQ ver-
sus 8.0% in the DTaP3-HB-IPV/Hib group.
For the secondary endpoint of GMCs assessed at 4 years
after completion of the original 2 + 1 vaccination schedule,
persistence of pertussis-related antibodies was generally con-
sistent with post-primary immunization levels. Anti-PT and
anti-FIM GMCs were higher, anti-FHA was lower, and anti-
PRN GMCs were similar in the DTaP5-HB-IPV-Hib group
compared with the DTaP3-HB-IPV/Hib group (Table 4).
Safety
No SAEs related to study procedures were reported during the
study period.
Table 1. Demographic characteristics of the persistence analysis set.
3 + 1 2 + 1
Parameter
Group 1
(N = 191)
Group 2
(N = 189)
All
(N = 380)
Group 3
(N = 181)
Group 4
(N = 191)
All
(N = 372)
All
(N = 752)
Gender, n (%)
Female 98 (51.3) 86 (45.5) 184 (48.4) 84 (46.4) 94 (49.2) 178 (47.8) 362 (48.1)
Male 93 (48.7) 103 (54.5) 196 (51.6) 97 (53.6) 97 (50.8) 194 (52.2) 390 (51.9)
Mean age at toddler dose in previous study, months (SD) 12.2 (0.4) 12.2 (0.4) 12.2 (0.4) 11.2 (0.4) 11.2 (0.4) 11.2 (0.4) 11.7 (0.6)
Mean age at the persistence time point, months (SD) 4.8 (0.2) 4.8 (0.2) 4.8 (0.2) 3.9 (0.1) 3.9 (0.1) 3.9 (0.1) 4.4 (0.4)
Mean weight at the persistence time point, kg (SD) 19.2 (2.5) 19.3 (2.6) 19.2 (2.6) 16.9 (2.1) 17.3 (2.4) 17.1 (2.3) 18.2 (2.6)
SD, standard deviation.
Group 1: DTaP5-HB-IPV-Hib (3 + 1): those previously vaccinated with a 3-dose primary series and a toddler dose of DTaP5-HB-IPV-Hib.
Group 2: DTaP3-HB-IPV/Hib (3 + 1): those previously vaccinated with a 3-dose primary series and a toddler dose of DTaP3-HB-IPV/Hib.
Group 3: DTaP5-HB-IPV-Hib (2 + 1): those previously vaccinated with a 2-dose primary series and a toddler dose of DTaP5-HB-IPV-Hib.
Group 4: DTaP3-HB-IPV/Hib (2 + 1): those previously vaccinated with a 2-dose primary series and a toddler dose of DTaP3-HB-IPV/Hib.
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Discussion
This immunogenicity study demonstrated the long-term per-
sistence of hepatitis B antibodies following the administration
of DTaP5-HB-IPV-Hib as a 3-dose primary series given at 2,
3, and 4 months of age and a toddler dose at 12 months of
age, or a 2-dose primary series given at 2 and 4 months of age
and a toddler dose at 11 to 12 months, and the persistence of
pertussis antibodies after the latter vaccination schedule. In
this study, the threshold for seroprotection was anti-HBs
concentrations ≥10 mIU/mL, which is a widely accepted
immune correlate of protection against hepatitis B virus
infection.16 In contrast, pertussis lacks a simple correlate of
protection, although logistic regression analysis of immune
responses from household-exposed cohorts within acellular
pertussis vaccine efficacy studies demonstrated statistically
significant associations between the presence of antibodies
against pertactin, fimbriae 2/3, and pertussis toxin, and clin-
ical protection from pertussis.17,18
Anti-HBs results in this persistence study were consistent
with those from the original studies, which showed similarly
high rates of children with anti-HBs ≥10 and ≥100 mIU/mL
for both DTaP5-HB-IPV-Hib and DTaP3-HB-IPV/Hib, with
higher GMCs for the DTaP3-HB-IPV/Hib vaccine. All anti-
HBs levels are expected to wane over time, regardless if from
infection or vaccination, with anti-HBs protective level con-
centrations declining rapidly within the first year (down to
15%–50%) and more slowly thereafter (low or undetectable
after 5–15 years). However, lower anti-HBs concentrations
years after vaccination do not indicate the absence of protec-
tion against clinically important hepatitis B disease. It is well
documented and accepted by international public health
authorities that initial seroprotection following a complete
series of hepatitis B vaccination determines long-term protec-
tion, and robust seroprotection rates following vaccination
were observed in the original studies. After disappearance of
vaccine-induced circulating antibodies, protection against
hepatitis B results from an immune memory response.19–29
This immune memory or anamnestic response years after
vaccination with hepatitis B-containing vaccine can be
demonstrated with a challenge dose of hepatitis B vaccine,
Table 2. Summary of anti-HBs responses: persistence analysis set.
Post-infant Post-toddler Persistence
Schedule Parameter DTaP5-HB-IPV-Hib DTaP3-HB-IPV/Hib DTaP5-HB-IPV-Hib DTaP3-HB-IPV/Hib DTaP5-HB-IPV-Hib DTaP3-HB-IPV/Hib
3 + 1 n 162 165 186 186 Group 1: 191 Group 2: 189
% ≥10 mIU/mL 98.8 97.0 100.0 100.0 70.2 82.0
(95% CI) (95.6, 99.9) (93.1, 99.0) (98.0, 100.0) (98.0, 100.0) (63.1, 76.5) (75.8, 87.2)
% ≥100 mIU/mL 79.6 84.2 96.8 98.4 18.3 39.7
(95% CI) (72.6, 85.5) (77.8, 89.4) (93.1, 98.8) (95.4, 99.7) (13.1, 24.6) (32.7, 47.0)
GMC, EU/mL 230 271 3085 4157 24.4 51.3
(95% CI) (190, 278) (225, 326) (2529, 3762) (3403, 5077) (19.5, 30.6) (40.2, 65.5)
2 + 1 n 104 110 124 131 Group 3: 181 Group 4: 190
% ≥10 mIU/mL 99.0 98.2 100 100 65.7 83.7
(95% CI) (94.8, 100) (93.6, 99.8) (97.1, 100) (97.2, 100) (58.3, 72.6) (77.6, 88.6)
% ≥100 mIU/mL 80.8 86.4 97.6 97.7 17.7 45.3
(95% CI) (71.9, 87.8) (78.5, 92.2) (93.1, 99.5) (93.5, 99.5) (12.4, 24.0) (38.0, 52.6)
GMC, EU/mL 255 450 2413 4271 19.4 71.0
(95% CI) (199, 327) (348, 580) (1946, 2992) (3334, 5470) (15.5, 24.4) (54.9, 91.8)
Anti-HBs, anti-hepatitis B surface antigen; CI, confidence interval; EU, ELISA units; GMC, geometric mean concentration; IU, international units.
Table 3. Summary of pertussis antibodies persistence (responses rate) following a 2 + 1 schedule: persistence analysis set.
Group 3 Group 4
Antibody Concentration Endpointb N n (%) 95% CIa N n (%) 95% CIa
Anti-PT ≥LLOQb 178 104 (58.4) 50.8, 65.8 188 78 (41.5) 34.4, 48.9
≥2xLLOQ 72 (40.5) 33.2, 48.1 41 (21.8) 16.1, 28.4
≥4xLLOQ 26 (14.6) 9.8, 20.7 7 (3.7) 1.5, 7.5
Anti-FHA ≥LLOQ 173 140 (80.9) 74.3, 86.5 188 166 (88.3) 82.8, 92.5
≥2xLLOQ 81 (46.8) 39.2, 54.5 133 (70.7) 63.7, 77.1
≥4xLLOQ 45 (26.0) 19.7, 33.2 85 (45.2) 38.0, 52.6
Anti-PRN ≥LLOQ 180 119 (66.1) 58.7, 73.0 190 138 (72.6) 65.7, 78.8
≥2xLLOQ 79 (43.9) 36.5, 51.5 97 (51.1) 43.7, 58.4
≥4xLLOQ 28 (15.6) 10.6, 21.7 35 (18.4) 13.2, 24.7
Anti-FIM ≥LLOQ 177 167 (94.4) 89.9, 97.3 183 6 (3.3) 1.2, 7.0
≥2xLLOQ 156 (88.1) 82.4, 92.5 4 (2.2) 0.6, 5.5
≥4xLLOQ 123 (69.5) 62.1, 76.2 2 (1.1) 0.1, 3.9
aConfidence intervals were calculated based on the exact binomial method of D. Collett.15
bLower limit of quntification (LLOQ) = 4 EU/mL for PT, PRN, and FIM; LLOQ = 3 EU/mL for FHA.
CI, confidence interval; FHA, filamentous hemagglutinin; FIM, fimbriae; PRN, pertactin; PT, pertussis toxin.
Table 4. Summary of pertussis antibodies persistence (GMCs) following a 2 + 1
schedule: persistence analysis set.
Group 3
(N = 173–180)
Group 4
(N = 183–190)
Anti-PT
GMC, EU/mL (95% CI) 5.3 (4.6, 6.1) 3.6 (3.2, 4.1)
Anti-FHA
GMC, EU/mL (95% CI) 6.6 (5.5, 7.9) 11.1 (9.1, 13.4)
Anti-PRN
GMC, EU/mL (95% CI) 5.9 (5.1, 6.9) 7.2 (6.2, 8.3)
Anti-FIM
GMC, EU/mL (95% CI) 26.0 (21.9, 30.9) 2.1 (2.0, 2.3)
CI, confidence interval; EU, ELISA units; FHA, filamentous hemagglutinin; FIM,
fimbriae; GMC, geometric mean concentration; PRN, pertactin; PT, pertussis toxin.
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which is composed of hepatitis B surface antigen and serves as
a model of exposure to hepatitis B virus itself. Years after
primary hepatitis B vaccination, children and adults demon-
strate high rates of seroprotective antibody responses follow-
ing a challenge dose of hepatitis B vaccine, including
individuals with anti-HBs <10 mIU/mL prior to the
challenge.30 Such anamnestic responses have been demon-
strated as long as 22 years after infant and childhood vaccina-
tion with recombinant or plasma-derived hepatitis B vaccine
in Taiwan,19 and 30 years after vaccination with plasma-
derived hepatitis B vaccine in Alaska.31 Immunologic charac-
terization of the 30-year Alaskan cohort showed that immune
memory against hepatitis B correlated with the presence of
natural killer T-cell responses.32 Similarly high rates of sero-
protection have been demonstrated in response to hepatitis
B challenge dosing years after primary vaccination with hepa-
titis B-containing hexavalent vaccines.33–36 These immune
memory mechanisms are posited to include responses
mediated by natural killer T cells. Given that there are no
approved clinical tests for cell-mediated immune memory
markers against hepatitis B, it is reasonable to monitor for
anti-HBs ≥10 mIU/mL after vaccination in the research set-
ting, while understanding that it does not provide the com-
plete view of immune protection against hepatitis B resulting
from vaccination. Accordingly, there are no public health
recommendations for long-term monitoring of anti-HBs,
nor are there routine hepatitis B booster dose recommenda-
tions based on anti-HBs levels years after vaccination.
In addition to long-term immune memory, the long-term
efficacy and effectiveness of hepatitis B vaccination has been
confirmed in cohort studies, and by real-world evidence,
respectively. Multiple long-term follow-up cohort studies
have demonstrated high rates of protection from chronic car-
rier state (HBs positivity) and infection (hepatitis B core anti-
gen positivity), following vaccination for 15 to 22 years.19–27,29
Countries that have adopted universal vaccination against
hepatitis B with recombinant HBV have seen dramatic
decreases in hepatitis B disease rates21,37 consistent with the
high effectiveness of hepatitis B vaccination during infancy.
Given the high long-term efficacy and effectiveness of infant
hepatitis B vaccination, routine booster vaccination against
hepatits B is not recommended by a number of global organi-
zations, including the World Health Organization, US Centers
for Disease Control and Prevention, the Standing Committee
on Vaccination at the Robert Koch Institute (STIKO), and the
Viral Hepatitis Prevention Board.38,39
In a prior study of concomitant vaccination between
a hepatitis B-containing hexavalent vaccine (DTaP-IPV-HBV-
Hib [Hexavac], Aventis Pasteur MSD, Lyon, France) and
a 7-valent pneumococcal conjugate vaccine (Prevnar 7,
Wyeth), lower hepatitis B GMCs were noted with concomitant
administration as opposed to separate administration.40 In order
to overcome potential immune interference among hexavalent
vaccine components, or with concomitant vaccine antigens,
DTaP5-HB-IPV-Hib has been designed to optimize hepatitis
B immunogenicity, with an increase from 5 to 10 µg of the
HBs component, and a modified process aluminum phosphate
adjuvant, which allows for greater accessibility of the adsorbed
hepatitis B antigen to antigen-presenting cells.41 Multiple
randomized, double-blind, comparator-controlled studies of
hepatitis B vaccine with modified process adjuvant, demon-
strated similar safety and higher hepatitis B GMCs compared
with hepatitis B vaccine with original process adjuvant in a wide
range of populations from infants to older adults.42–46
Accordingly, the hepatitis B responses in the Phase 3 studies of
DTaP5-HB-IPV-Hib have been robust, meeting all acceptability
and non-inferiority criteria compared with the licensed vaccine
regimens in the United States and Europe (pentavalent with
separate monovalent hepatitis B, or DTaP3-HB-IPV/Hib,
respectively). Indeed, as highlighted in the current manuscript,
DTaP5-HB-IPV-Hib resulted in high and similar percentages of
children with anti-HBs ≥10 and ≥100 mIU/mL compared with
DTaP3-HB-IPV/Hib in the rigorous settings of the European
Union (ie, without a hepatitis B birth dose and using
a compressed 3-dose [2, 3, 4 months] or 2-dose [2, 4 months]
regimen). Note that the increase in the ratio of aluminum
phosphate to aluminum hydroxide in the modified process
adjuvant does not result in higher total amounts of aluminum
salt in DTaP5-HB-IPV-Hib (314 μg) as compared to DTaP3-HB
-IPV/Hib (950 μg).
This study also provides information about the long-term
persistence of pertussis antibody responses following the
administration of DTaP5-HB-IPV-Hib as a 2-dose primary
series given at 2 and 4 months of age, with a toddler dose at
11 to 12 months of age. Pertussis antibodies 3 to 4 years
following a 2 + 1 hexavalent dosing schedule were higher in
DTaP5-HB-IPV-Hib recipients for anti-PT and anti-FIM anti-
bodies compared with those who received the DTaP3-HB-IPV
/Hib vaccine. Levels of anti-FHA antibodies were higher in
DTaP3-HB-IPV/Hib recipients compared with DTaP5-HB-
IPV-Hib recipients, while anti-PRN antibodies were compar-
able across both vaccine groups. There are differing quantities
of pertussis antigens in each 0.5-mL dose of the study vac-
cines. DTaP5-HB-IPV-Hib contains 20 µg PT, 20 µg FHA,
3 µg PRN and 5 µg FIM. In contrast, DTaP3-HB-IPV/Hib
contains 25 µg PT, 25 µg FHA, 8 µg PRN and no FIM. The
anti-pertussis anibody levels found in this study generally
correlated with the pertussis antigen quantities in the respec-
tive vaccines, with the exception of PT antibody. Factors in
addition to antigen quantity, such as source and formulation,
may explain this somewhat counterintuitive finding.47
In this study, anti-PT, anti-FHA, and anti-PRN GMCs had
fallen for both vaccine groups back to the pre-vaccination levels
in the original 2 + 1 study, while the anti-FIM GMC in the
DTaP5-HB-IPV-Hib group persisted well above baseline levels.
Although some have suggested that there are no serological
correlates of protection, the oposite is actually the case.
However, these correlates are multiple and complex.48
A validated model of pertussis protection,17,18 as well as other
investigations,49,50 suggest that higher levels of anti-FIM anti-
bodies, as seen in the DTaP5-HB-IPV-Hib group of the present
study, may be associated with enhanced pertussis
immunity.17,18,50 In spite of the persistence of anti-FIM antibo-
dies in the DTaP5-HB-IPV-Hib receipients, the overall pertussis
antibody findings of this study reinforce the importance of
following recommendations for school-entry pertussis booster
vaccination at around 5 years of age, as is done in the United
States and the majority of countries in the European Union.51,52
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Limitations of this study include that it was descriptive and
not powered for formal between-groups comparisons, and the
monitoring of immune memory against hepatitis B was limited
to tests approved for clinical use (anti-HBs levels). In addition,
the study design only evaluated the persistence of anti-HBs and
did not measure the response to a challenge dose of hepatitis
B vaccine, which models exposure to hepatitis B.
In conclusion, this study demonstrated that although anti-
HBs levels ≥10 IU/mL and detectable antibodies against acellular
pertussis antigens persisted in a majority of study participants,
there was waning of hepatitis B and pertussis antibodies during
the 3 to 4 years after completion of the infant-toddler hexavalent
vaccination schedule. These findings have different clinical and
public health implications for the long-term prevention of these
diseases. Regarding hepatitis B vaccination, responders to
a complete series continue to be protected against hepatitis
B disease and chronic infection, regardless of the level of circu-
lating anti-HBs at the time of their exposure to hepatitis B virus.
For pertussis, the waning of most anti-pertussis antibodies to
prevaccination basline levels support pertussis booster vaccina-
tion at school-entry and beyond.
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